California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
SAN DIEGO, Nov. 22, 2016 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that Chairman and Chief Executive Officer Keith Murphy is scheduled to speak at the 28th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 29th at 4:00 p.m. Eastern Time (ET). The presentation will be simultaneously audio webcast at http://www.organovo.com. The audio webcast will be archived for 90 days following the conference.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
Investor Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 [email protected] Press Contact: Jessica Yingling Little Dog Communications +1 (858) 480-2411 [email protected]
